Steven R. Steinhubl, MD

The Influence of Body Mass Index on Outcomes and the Benefit of Antiplatelet Therapy following Percutaneous Coronary Interventio

08/01/2008

Amy Hsu , MD, MS;

Steven R. Steinhubl , MD;

Eric J. Topol , MD;

Robert V. Kelly , MD;

Obesity affects over 20% of the U.S. population and most countries in the developing world.1,2 It is an independent risk factor for premature coronary artery disease and is associated with an increase in cardiac morbidity and mortality,...

Obesity affects over 20% of the...

08/01/2008

Journal of Invasive Cardiology

Feature

Antiplatelet Therapy: Aspirin

08/01/2008

Steven R. Steinhubl , MD;

History of aspirin. Although aspirin’s active ingredient has been used for medicinal purposes for centuries, there is still much we don’t know about it. In fact, the first published research is from 1763 entitled “An Account of the Success of...

History of aspirin. Although...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Efficacy of a Novel Procedure Sheath and Closure Device during
Diagnostic Catheterization: The Multicenter Randomized Clinical

08/01/2008

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Anthony A. Bravry , MD, MPH;

Russell E. Raymond , DO;

Charles E. Chambers , MD;

Andrew J. DeNardo , MD;

James B. Hermiller , MD, FACC, FSCAI;

Paul R. Myers , MD;

Douglas E. Pitts , MD;

John A. Scott , MD;

Scott J. Savader , MD;

Steven R. Steinhubl , MD;

Multiple devices are currently available for closure of the femoral artery access site after cardiac catheterization.1 Currently, the most widely used closure devices are the Angio-Seal™ device (St. Jude Medical, St. Paul, Minnesota)2–4 and...

Multiple devices are currently...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention Reduces Ischemic Events without Affecting the Need

08/01/2008

Sorin J. Brener , MD;

Steven R. Steinhubl , MD;

Eric J. Topol , MD;

Danielle M. Brennan , MS;

Peter B. Berger , MD;

When clopidogrel is added to background aspirin therapy, it reduces the composite of cardiovascular death, myocardial infarction (MI) or stroke in patients with acute coronary syndromes (ACS)1 or percutaneous revascularization.2 The most...

When clopidogrel is added to...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Impact of Drug-Eluting Stents on Outcomes of Patients with
End-Stage Renal Disease Undergoing Percutaneous Coronary Revasculari

08/01/2008

Khaled M. Ziada , MD;

David J. Moliterno , MD;

Richard Charnigo , MD;

J. Darrell Sneed , MD;

David C. Booth , MD;

Debabrata Mukherjee , MD, MS;

Pranab Das , MD;

Steven R. Steinhubl , MD;

Several randomized trials have demonstrated the efficacy of drug-eluting stents (DES) in reducing restenosis and the need for target vessel revascularization (TVR) in comparison to bare metal stents (BMS).1-3 Patient and lesion subsets...

Several randomized trials have...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Timing and Correlates of Very Early Major Adverse Clinical Events Following Percutaneous Coronary Intervention

08/01/2008

Peter B. Berger , MD;

James L. Orford , MBChB, MPH, MD;

Joseph Jozic , MD;

Amy Hsu , MD, MS;

Steven R. Steinhubl , MD;

Eric J. Topol , MD;

The timing of, and risk factors for, very early (< 24 hours) major adverse clinical events (death, myocardial infarction [MI], urgent target vessel revascularization [uTVR], and major bleeding) following percutaneous coronary intervention...

The timing of, and risk factors...

08/01/2008

Journal of Invasive Cardiology